Cargando…
Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials
This study aims to investigate the efficacy of targeted therapies in the treatment of non-small cell lung cancer (NSCLC) by using a network meta-analysis of clinical trials. PubMed, EMBASE, Cochrane Library, and Clinicaltrials.gov were searched by using keywords related to the topic on 19 September...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230601/ https://www.ncbi.nlm.nih.gov/pubmed/32283699 http://dx.doi.org/10.3390/jcm9041063 |
_version_ | 1783534992687628288 |
---|---|
author | Hoang, Tung Myung, Seung-Kwon Pham, Thu Thi Kim, Jeongseon Ju, Woong |
author_facet | Hoang, Tung Myung, Seung-Kwon Pham, Thu Thi Kim, Jeongseon Ju, Woong |
author_sort | Hoang, Tung |
collection | PubMed |
description | This study aims to investigate the efficacy of targeted therapies in the treatment of non-small cell lung cancer (NSCLC) by using a network meta-analysis of clinical trials. PubMed, EMBASE, Cochrane Library, and Clinicaltrials.gov were searched by using keywords related to the topic on 19 September 2018. Two investigators independently selected relevant trials by pre-determined criteria. A pooled response ratio (RR) for overall response rate (ORR) and a hazard ratio (HR) for progression-free survival (PFS) were calculated based on both the Bayesian and frequentist approaches. A total of 128 clinical trials with 39,501 participants were included in the final analysis of 14 therapeutic groups. Compared with chemotherapy, both ORR and PFS were significantly improved for afatinib, alectinib, and crizotinib, while only PFS was significantly improved for cabozantinib, ceritinib, gefitinib, and osimertinib. Consistency was observed between the direct and indirect comparisons based on the Bayesian approach statistically and the frequentist approach visually. Cabozantinib and alectinib showed the highest probability for the first-line treatment ranking in ORR (62.5%) and PFS (87.5%), respectively. The current network meta-analysis showed the comprehensive evidence-based comparative efficacy of different types of targeted therapies, which would help clinicians use targeted therapies in clinical practice. |
format | Online Article Text |
id | pubmed-7230601 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72306012020-05-22 Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials Hoang, Tung Myung, Seung-Kwon Pham, Thu Thi Kim, Jeongseon Ju, Woong J Clin Med Article This study aims to investigate the efficacy of targeted therapies in the treatment of non-small cell lung cancer (NSCLC) by using a network meta-analysis of clinical trials. PubMed, EMBASE, Cochrane Library, and Clinicaltrials.gov were searched by using keywords related to the topic on 19 September 2018. Two investigators independently selected relevant trials by pre-determined criteria. A pooled response ratio (RR) for overall response rate (ORR) and a hazard ratio (HR) for progression-free survival (PFS) were calculated based on both the Bayesian and frequentist approaches. A total of 128 clinical trials with 39,501 participants were included in the final analysis of 14 therapeutic groups. Compared with chemotherapy, both ORR and PFS were significantly improved for afatinib, alectinib, and crizotinib, while only PFS was significantly improved for cabozantinib, ceritinib, gefitinib, and osimertinib. Consistency was observed between the direct and indirect comparisons based on the Bayesian approach statistically and the frequentist approach visually. Cabozantinib and alectinib showed the highest probability for the first-line treatment ranking in ORR (62.5%) and PFS (87.5%), respectively. The current network meta-analysis showed the comprehensive evidence-based comparative efficacy of different types of targeted therapies, which would help clinicians use targeted therapies in clinical practice. MDPI 2020-04-09 /pmc/articles/PMC7230601/ /pubmed/32283699 http://dx.doi.org/10.3390/jcm9041063 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hoang, Tung Myung, Seung-Kwon Pham, Thu Thi Kim, Jeongseon Ju, Woong Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials |
title | Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials |
title_full | Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials |
title_fullStr | Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials |
title_full_unstemmed | Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials |
title_short | Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials |
title_sort | comparative efficacy of targeted therapies in patients with non-small cell lung cancer: a network meta-analysis of clinical trials |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230601/ https://www.ncbi.nlm.nih.gov/pubmed/32283699 http://dx.doi.org/10.3390/jcm9041063 |
work_keys_str_mv | AT hoangtung comparativeefficacyoftargetedtherapiesinpatientswithnonsmallcelllungcanceranetworkmetaanalysisofclinicaltrials AT myungseungkwon comparativeefficacyoftargetedtherapiesinpatientswithnonsmallcelllungcanceranetworkmetaanalysisofclinicaltrials AT phamthuthi comparativeefficacyoftargetedtherapiesinpatientswithnonsmallcelllungcanceranetworkmetaanalysisofclinicaltrials AT kimjeongseon comparativeefficacyoftargetedtherapiesinpatientswithnonsmallcelllungcanceranetworkmetaanalysisofclinicaltrials AT juwoong comparativeefficacyoftargetedtherapiesinpatientswithnonsmallcelllungcanceranetworkmetaanalysisofclinicaltrials |